Laboratorios Normon S.A. — Sponsor Intelligence | 28 EU Trials

Filter these 28 trials by condition, phase, country and more.

Open in Search →

28 Registered trials

2 Recruiting

26 Completed trials

2 Countries active

11 Unique IMPs

100% Results reported

Other

Phase III: 2 Phase II: 1 Other: 25

Oversight events:

1 temporary halt across 1 trial

View oversight register →

100%

26 of 26 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Actinic keratosis 1 Streptococcal impetigo 1 Staphylococcal impetigo 1 Impetigo 1 Bullous impetigo 1

Top IMPs

ATORVASTATIN CALCIUM, EZETIMIBE 3 ATORVASTATIN, EZETIMIBE 3 VALSARTAN, SACUBITRIL 2 ACICLOVIR 1 APIXABAN 1 EZETIMIBE, ROSUVASTATIN 1 EZETIMIBE, ROSUVASTATIN ZINC 1 HYDROCHLOROTHIAZIDE 1 IMIQUIMOD 1 MUPIROCIN 1 PREGABALIN 1

All trials

28 total

Clinical trial to evaluate the efficacy and safety of the topical application of Impetine® Gel (mupirocin 20 mg/g) compared with Bactroban® … Recruiting

2024-517475-20-00 Phase III 1 country MUPIROCIN
Clinical trial to investigate the efficacy and tolerability of Lipovir® Gel (Acyclovir 5%) compared to Zovirax® Cream (Acyclovir 5%) and pla… Recruiting

2023-510338-10-00 Phase III 1 country ACICLOVIR
An exploratory, multicenter, randomized, open-label with blind evaluation, active controlled study to evaluate the safety and efficacy of Ke… Ended

2024-515667-60-00 Phase II 1 country IMIQUIMOD
Bioequivalence clinical trial of two formulations of canagliflozin Ended

2026-525944-14-00 1 country
Bioequivalence clinical trial of two formulations of loperamide. Ended

2026-525278-20-00 1 country
Bioequivalence clinical trial of two formulations of loperamide. Ended

2025-523705-14-00 1 country
Bioequivalence clinical trial of two formulations of linagliptin Ended

2025-523384-37-00 1 country
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin Ended

2024-510791-20-00 1 country
Bioequivalence clinical trial of two formulations of loperamide. Ended

2025-521549-26-00 1 country
Bioequivalence clinical trial of two formulations of dapagliflozin/metformin Ended

2024-514050-75-01 1 country
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin Ended

2024-520303-62-00 1 country
Bioequivalence clinical trial of two formulations of vortioxetine. Ended

2024-519398-21-00 1 country
Bioequivalence clinical trial of two formulations of linagliptin/metformin. Ended

2024-516081-11-00 1 country
Bioequivalence clinical trial of two formulations of linagliptin/metformin Ended

2024-515076-13-00 1 country
Bioequivalence clinical trial of two formulations of loperamide. Ended

2024-515531-29-00 1 country
Bioequivalence clinical trial of two formulations of bilastine. Ended

2024-515077-96-00 1 country
Bioequivalence clinical trial of two formulations of dapagliflozin. Ended

2023-506561-62-00 1 country
Bioequivalence clinical trial of two formulations of linagliptin Ended

2023-506562-31-00 1 country
Bioequivalence clinical trial of two formulations of edoxaban. Ended

2024-510795-20-00 1 country
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin Ended

2023-507226-16-00 1 country ATORVASTATIN CALCIUM, EZETIMIBE; ATORVASTATIN, EZETIMIBE
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin Ended

2023-506559-10-00 1 country ATORVASTATIN CALCIUM, EZETIMIBE; ATORVASTATIN, EZETIMIBE
Bioequivalence clinical trial of two formulations of hydrochlorothiazide. Ended

2023-505692-72-00 1 country HYDROCHLOROTHIAZIDE
Bioequivalence clinical trial of two formulations of ezetimibe/atorvastatin Ended

2023-504987-40-00 1 country ATORVASTATIN CALCIUM, EZETIMIBE; ATORVASTATIN, EZETIMIBE
Bioequivalence clinical trial of two formulations of sacubitril/valsartan Ended

2023-505237-27-00 1 country VALSARTAN, SACUBITRIL

Showing 1–24 of 28 trials

← All sponsors A–Z